Clinical Trials

69 results for Prostate Cancer


Prospective Evaluation of CyberKnife® as Monotherapy or Boost Stereotactic Body Radiotherapy for Intermediate or High Risk Localized Prostate Cancer

  • Condition: Prostate Adenocarcinoma
  • Intervention: Radiation: CyberKnife, Other: Androgen Deprivation Therapy (ADT), Radiation: Intensity Modulated radiation therapy (IMRT)
  • Study ID: NCT01985828
View Trial

A Pilot Study of Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) to Detect High Grade Localized Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Drug: Pyruvate (13C)
  • Study ID: NCT02526368
View Trial

The UCLA ASCAP Project is an Observational, Longitudinal, and Open-ended Study Aimed at Establishing a Structured Program of Non-interventional Follow-up for Localized Prostate Cancer.

  • Condition: Prostate Cancer
  • Intervention: Other: Active surveillance
  • Study ID: NCT00949819
View Trial

Prospective Evaluation of CyberKnife Stereotactic Body Radiotherapy for Localized Prostate Cancer: Risk Stratified Monotherapy Versus Boost

  • Condition: Prostate Cancer
  • Study ID: NCT02016248
View Trial

Perioperative Pelvic Floor Muscle Training May Improve Recovery of Continence in Men With Localized Prostate Cancer Undergoing Robot-Assisted Radical Prostatectomy

  • Condition: Prostate Cancer, Urinary Incontinence, Pelvic Floor Physical Therapy
  • Study ID: NCT02558946
View Trial

Primary Radical Prostatectomy Versus Primary Radiotherapy for Locally Advanced Prostate Cancer: an Open Randomized Clinical Trial

  • Condition: Prostatic Neoplasms
  • Intervention: Procedure: Prostatectomy/Surgery, Other: Radiotherapy with adjuvant androgen deprivation therapy
  • Study ID: NCT02102477
View Trial

Focal Low Dose Rate ( LDR) Brachytherapy: Hemi-ablative Treatment With LDR for Patients With Low and Low-tier Intermediate Risk Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Radiation: Transperineal template guided mapping biopsy, multiparametric MRI, Hemiablative Focal Brachytherapy
  • Study ID: NCT02643511
View Trial

Safety and Early Efficacy of Radical Prostatectomy for Newly Diagnosed Very High Risk Locally Advanced and Oligometastatic Prostate Cancer - a Prospective Single Center Phase I/II Study

  • Condition: Locally Advanced and Metastatic Prostate Cancer
  • Intervention: Procedure: Radical prostatectomy
  • Study ID: NCT02971358
View Trial

Phase III Study of Image Guided Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Adenocarcinoma of the Prostate

  • Condition: Prostate Cancer
  • Intervention: Radiation: Radiation, Drug: Androgen Suppression Therapy
  • Study ID: NCT01492972
View Trial

Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)

  • Condition: Prostatic Neoplasms
  • Study ID: NCT02861573
View Trial

Collection of Blood From Patients With Prostate Cancer

  • Condition: Prostatic Neoplasms
  • Study ID: NCT00923221
View Trial

Canary Prostate Active Surveillance Study

  • Condition: Prostatic Neoplasms
  • Study ID: NCT00756665
View Trial

[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Drug: [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone
  • Study ID: NCT00588185
View Trial

A Pilot Study of High Dose Rate Brachytherapy in The Radiation Oncology Branch

  • Condition: Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Prostate Cancer, Biliary Cancer
  • Study ID: NCT00924027
View Trial

Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene and Characterization of the Predisposition to Renal Cancer

  • Condition: Renal Tumor Histology, Cutaneous Leiomyomatosis, Kidney Cancer
  • Study ID: NCT00050752
View Trial

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

  • Condition: Malignant Neoplasms, Hereditary Neoplastic Syndromes, Kidney Cancer, Renal Cancer
  • Study ID: NCT00026884
View Trial

Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy

  • Condition: Prostate Cancer
  • Intervention: Radiation: IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE, Radiation: Proton (prostate bed) to 70.2 CGE, Radiation: IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE, Radiation: Proton to 66.6 CGE
  • Study ID: NCT00969111
View Trial

A Randomized Trial of Modifications to Radical Prostatectomy

  • Condition: Prostate Cancer
  • Intervention: Procedure: Lymph node template, Procedure: Transverse versus vertical closure, Drug: antibiotic prophylaxis
  • Study ID: NCT01407263
View Trial

Collection of Blood From Patients With Cancer for Analysis of Genetic Differences in Drug Disposition

  • Condition: Prostate Cancer, Breast Cancer, Lung Cancer, Ovarian Cancer, Lymphoma
  • Study ID: NCT01441089
View Trial

Biospecimen Acquisition From Human Subjects

  • Condition: Prostate Cancer, Breast Cancer, Colon Cancer, Lung Cancer, Liver Cancer
  • Study ID: NCT00034216
View Trial

Carbon Ion Radiotherapy for the Treatment of Localized Prostate Cancer

  • Condition: Prostate Carcinoma
  • Study ID: NCT02739659
View Trial

HDR Monotherapy for Prostate Cancer: A Feasibility Study of Focal Radiotherapy Yields

  • Condition: Prostate Cancer
  • Intervention: Radiation: targeted focal HDR brachytherapy, Radiation: Whole-gland HDR Brachytherapy
  • Study ID: NCT02918253
View Trial

Phase II Study: [18F]DCFPyL PET/MRI for Personalizing Prostate Cancer Subclinical Metastatic Ablative MR-guided Radiotherapy (MRgRT)

  • Condition: Post Prostatectomy
  • Intervention: Diagnostic Test: [18F]DCFPyL PET/MRI scan, Radiation: Stereotactic Ablative Radiotherapy
  • Study ID: NCT03160794
View Trial

Diagnosing Clinically Significant Prostate Cancer in African American and White Men Phase II, Randomized Clinical Trial, Multi-center, MR-Guided vs. 12-core Systematic Random Biopsy, Localized Prostate Cancer

  • Condition: Health Status Unknown, PSA Progression
  • Intervention: Procedure: Biopsy of Prostate, Other: Laboratory Biomarker Analysis, Diagnostic Test: Magnetic Resonance Imaging, Diagnostic Test: MRI Ultrasound Fusion Guided Biopsy
  • Study ID: NCT03234556
View Trial

PHASE I STUDY OF PSMA-TGFβRDN CAR MODIFIED T CELLS IN PATIENTS WITH ADVANCED CASTRATE RESISTANT PROSTATE CANCER

  • Condition: Prostate Cancer
  • Study ID: NCT03089203
View Trial

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

  • Condition: Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
  • Intervention: Drug: Abiraterone, Drug: Bicalutamide, Drug: Degarelix, Drug: Docetaxel, Drug: Flutamide, Drug: Goserelin Acetate, Drug: Histrelin Acetate, Drug: Leuprolide Acetate, Drug: Nilutamide, Procedure: Orchiectomy, Drug: Prednisone, Other: Quality-of-Life Assessment, Radiation: Radiation Therapy, Procedure: Radical Prostatectomy, Drug: Triptorelin
  • Study ID: NCT03678025
View Trial

Cystoprostatectomy Versus Radiotherapy Combined With Androgen Deprivation Therapy for the Treatment of Clinical T4 Prostate Cancer With Bladder Invasion: a Multicentre, Prospective, Open, Randomized Clinical Trial

  • Condition: Prostate Cancer
  • Intervention: Procedure: Cystoprostatectomy, Radiation: external beam radiotherapy
  • Study ID: NCT03482089
View Trial

Cytoreductive Prostatectomy Versus Cytoreductive Prostate Irradiation as a Local Treatment Option for Metastatic Prostate Cancer: a Multicentric Feasibility Trial

  • Condition: Prostate Cancer Metastatic
  • Study ID: NCT03655886
View Trial

High Dose Testosterone in Men With Advanced Prostate Cancer and Homologous Recombination Deficiency

  • Condition: Castration-resistant Prostate Cancer, Homologous Recombination Deficiency
  • Intervention: Drug: Testosterone Enanthate
  • Study ID: NCT03522064
View Trial

Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  • Condition: Prostate Cancer
  • Intervention: Drug: Docetaxel 75 mg/m2, Drug: Docetaxel 60 mg/m2, Drug: Radium-223
  • Study ID: NCT03574571
View Trial

Quality of Life in Patients With Clinically Localized Prostate Cancer Treated With Stereotactic Body Radiation Therapy (SBRT)

  • Condition: Prostate Cancer, Localized Malignant Neoplasm
  • Intervention: Radiation: Stereotactic Body Radiation Therapy (SBRT)
  • Study ID: NCT01766492
View Trial

Randomized, Multicentre Phase II Trial of the Sequencing of Radium-223 and Docetaxel Plus Prednisone in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer (mCRPC)

  • Condition: Metastatic Castration-resistant Prostate Cancer
  • Study ID: NCT03230734
View Trial

177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer

  • Condition: Metastatic Castration Resistant Prostate Cancer (mCRPC)
  • Study ID: NCT03874884
View Trial

A Phase 2 Study of a Checkpoint Inhibitor in Men With Progressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation

  • Condition: Metastatic Castration Resistant Prostate Cancer
  • Intervention: Drug: Pembrolizumab
  • Study ID: NCT04104893
View Trial

Phase II Trial of pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

  • Condition: Castration-resistant Prostate Cancer, Metastatic Cancer, Prostate Cancer
  • Intervention: Biological: pTVG-HP, Biological: pTVG-AR, Drug: Pembrolizumab, Drug: rhGM-CSF
  • Study ID: NCT04090528
View Trial

Phase II Study of Neoadjuvant Pembrolizumab Plus Intensive Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Drug: Pembrolizumab, Drug: Enzalutamide
  • Study ID: NCT03753243
View Trial

A Randomized Pilot Study Comparing High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy in Localized Prostate Cancer

  • Condition: Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
  • Intervention: Radiation: High-Dose Rate Brachytherapy, Other: Quality-of-Life Assessment, Other: Questionnaire Administration, Procedure: Stereotactic Ablative Radiotherapy
  • Study ID: NCT04253483
View Trial

ProBio: An Outcome-adaptive and Randomized Multi-arm Biomarker Driven Study in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

  • Condition: Metastatic Castration-Resistant Prostatic Cancer
  • Intervention: Drug: Enzalutamide Oral Capsule [Xtandi], Drug: Abiraterone Oral Tablet [Zytiga], Drug: Carboplatin, Drug: Cabazitaxel 60 mg Solution for Injection, Drug: Docetaxel Injectable Solution, Drug: Radium Chloride Ra-223
  • Study ID: NCT03903835
View Trial

A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer

  • Condition: Metastatic Castration-resistant Prostate Cancer
  • Intervention: Drug: REGN5678, Drug: Cemiplimab
  • Study ID: NCT03972657
View Trial

A Study to Evaluate the Safety and Efficacy of IMMU-132 (Sacituzumab Govitecan) in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on Second Generation AR-Directed Therapy

  • Condition: Prostate Cancer
  • Intervention: Drug: IMMU-132
  • Study ID: NCT03725761
View Trial

Phase I/II Dose-escalation Study of Fractionated and Multiple Dose 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

  • Condition: Prostate Cancer
  • Study ID: NCT04506567
View Trial

Early Detection of Prostate Cancer by Liquid Biopsy

  • Condition: Prostate Cancer
  • Study ID: NCT04556916
View Trial

Local Cytoreductive Treatments for Men With Newly Diagnosed Metastatic Prostate Cancer in Addition to Standard of Care Treatment

  • Condition: Prostate Cancer, Metastatic Prostate Cancer
  • Intervention: Combination Product: Standard of Care, Procedure: Minimally Invasive Ablative Therapy (MIAT), Procedure: Radical Therapy (Prostatectomy or Radiotherapy)
  • Study ID: NCT03763253
View Trial

A Phase IIA Study of Sequential ("First Strike, Second Strike") Therapies, Modeled on Evolutionary Dynamics of Anthropocene Extinctions, for High Risk Metastatic Castration Sensitive Prostate Cancer

  • Condition: Prostate Cancer, Stage IV Prostate Cancer
  • Study ID: NCT05189457
View Trial

Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)

  • Condition: Metastatic Malignant Neoplasm in the Bone, Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
  • Study ID: NCT04513717
View Trial

Randomized Phase II Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer

  • Condition: Prostate Cancer
  • Study ID: NCT04984343
View Trial

Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks

  • Condition: Prostate Cancer
  • Study ID: NCT04422132
View Trial

Feasibility Study of Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)

  • Condition: Prostate Cancer
  • Study ID: NCT05345444
View Trial

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

  • Condition: Prostate Adenocarcinoma
  • Study ID: NCT05050084
View Trial

A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): A-DREAM

  • Condition: Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
  • Study ID: NCT05241860
View Trial